Objective:
To evaluate the safety and efficacy of ONL1204, a Fas inhibitor, in reducing geographic atrophy (GA) lesion growth in patients.
Key Findings:
- ONL1204 demonstrated up to a 50% reduction in GA lesion growth at 6 months compared to sham-treated eyes.
- A single injection led to a 42% reduction in lesion growth compared to untreated fellow eyes.
- The treatment was well tolerated with minimal adverse events, and no cases of choroidal neovascularization or intraocular inflammation were observed.
Interpretation:
The results indicate that ONL1204 may provide significant neuroprotective benefits in GA, with potential implications for other retinal diseases characterized by cell death.
Limitations:
- The study was small and exploratory, limiting the generalizability of the findings.
- Further research is needed to confirm the efficacy and safety in larger populations.
Conclusion:
ONL1204 shows promise as a neuroprotective treatment for GA and may have broader applications in other retinal diseases. A phase 2 study is forthcoming.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.